1. Scrip
  2. >>Drug Pricing

UK's Crackdown On Anti-Competitive Deals Continues; Actavis In Firing Line Again

 
• By Lucie Ellis-Taitt

The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.

Wooden tower
UK competition authority continues to dismantal 'pay-for-delay' cases • Source: Shutterstock

The UK's Competition and Markets Authority (CMA) is once again cracking down on Actavis UK, this time alleging that the company signed illegal agreements with Concordia International Corp. that enabled Actavis's price hikes for generic hydrocortisone tablets to be prolonged in the UK. Over the last year, the CMA has fined Actavis once for its part in an anti-competitive deal with GlaxoSmithKline PLC and launched two investigations into its conduct in the UK.

In a March 3 statement, the CMA says a pay-for-delay agreement between Actavis and Concordia, which has spanned...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.